论文部分内容阅读
目的在前期制备出含羧基末端连接臂纳米脂质微泡的基础上,再在羧基末端连接抗体,制备出能够靶向HER2阳性乳腺癌细胞的纳米脂质微泡造影剂。方法采用碳二亚胺法制备携Herceptin纳米级靶向微泡造影剂,用制成的靶向微泡造影剂靶向HER2高表达乳腺癌细胞BT474和HER2表达阴性的乳腺癌细胞MDA-MB231,观察各自的微泡结合率。结果含羧基末端连接臂纳米脂质体微泡与Herceptin的结合率达90.8%;携Herceptin纳米级靶向微泡与HER2表达阳性的乳腺癌细胞结合率为81%;而与HER2表达阴性的乳腺癌细胞未见结合。结论所制备的靶向微泡造影剂能够与HER2表达阳性的乳腺癌细胞特异性结合,为HER2阳性乳腺癌的分子靶向显像奠定了基础。
OBJECTIVE To prepare nano-lipid microbubble contrast agent capable of targeting HER2-positive breast cancer cells based on the preparation of carboxyl-containing terminal tether nanolipid microbubbles in the early stage and then antibody binding at the carboxyl terminus. Methods Nanocapsule targeted microbubble agents bearing Herceptin were prepared by carbodiimide method. The targeting microbubble contrast agent was used to target HER2 highly expressed breast cancer cell line BT474 and HER2 negative breast cancer cell line MDA-MB231. Observe the respective microvesicle binding rate. Results The binding rate of nano-liposomes with carboxyl terminal linker to Herceptin was 90.8%. The binding rate of Herceptin-containing nano-targeting microbubbles to HER2-positive breast cancer cells was 81% No combination of cancer cells. Conclusion The targeted microbubble contrast agent can specifically bind to HER2 positive breast cancer cells and lay the foundation for the molecular targeted imaging of HER2 positive breast cancer.